Rui Chen1, Bin Ma2, Kehu Yang2, Jinhui Tian2, Yali Liu2, Li Zhao1. 1. The Centre of Evidence-Based Medicine, Lanzhou University, Lanzhou City, China ; Central Laboratory, The First Hospital of Lanzhou University, Lanzhou City, China. 2. The Centre of Evidence-Based Medicine, Lanzhou University, Lanzhou City, China.
Abstract
OBJECTIVE: This article compares the effect of interferon alfa plus cytarabine (IFN-alfa + Ara-C) versus IFN-alfa alone on the chronic phase of chronic myelogenous leukemia. METHODS: Electronic searches were performed in the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Chinese Biomedical Database, China Journal Full-text Database, and Chinese Scientific Journals Database. The languages were limited to Chinese and English. Randomized controlled trials were selected by 2 investigators. Analyses were performed using RevMan 5.0 software. RESULTS: A total of 3139 patients in 4 studies met the inclusion criteria. In those patients, complete hematologic response and cytogenetic responses showed significant improvements in favor of IFN-alfa + Ara-C, with complete hematologic response relative risk (RR) of 1.15 (95% CI, 1.09-1.21), complete cytogenetic response RR of 1.87 (95% CI, 1.47-2.38), partial cytogenetic response RR of 1.48 (95% CI, 1.25-1.75), and major cytogenetic response RR of 1.61 (95% CI, 1.42-1.83), respectively. The overall 3-year survival rate in the IFN-alfa + Ara-C group was 86% compared with 79% in the IFN-alfa group (RR = 1.09; 95% CI, 1.03-1.14). In the other 2 studies, 5-year overall survival was 69% compared with 63%, respectively (RR = 1.08; 95% CI, 1.01-1.15). However, IFN-alfa and Ara-C involved higher risk of hematologic toxicity, gastrointestinal adverse events, and severe mucositis compared with IFN-alfa monotherapy (RR = 2.63 [95% CI, 1.94-3.56); RR = 3.38 [95% CI, 2.28-5.00], and RR = 8.84 [95% CI, 3.82-20.46], respectively). Weight loss and skin rash were also observed more frequently in the combination treatment group (RR = 2.00 [95% CI, 1.47-2.73) and RR = 3.75 [95% CI, 2.13-6.59], respectively). CONCLUSIONS: In patients with chronic myelogenous leukemia in the chronic phase, the combination of IFN-alfa + Ara-C demonstrated improved complete hematologic response, superior cytogenetic responses, and higher rates of 3- and 5-year survival than IFN-alfa alone. However, combination therapy is more likely to cause serious adverse effects. Well-designed studies will be required to determine the outcomes and adverse effects of the 2 drugs as treatment for patients with chronic myelogenous leukemia who cannot afford molecularly targeted drugs.
OBJECTIVE: This article compares the effect of interferon alfa plus cytarabine (IFN-alfa + Ara-C) versus IFN-alfa alone on the chronic phase of chronic myelogenous leukemia. METHODS: Electronic searches were performed in the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Chinese Biomedical Database, China Journal Full-text Database, and Chinese Scientific Journals Database. The languages were limited to Chinese and English. Randomized controlled trials were selected by 2 investigators. Analyses were performed using RevMan 5.0 software. RESULTS: A total of 3139 patients in 4 studies met the inclusion criteria. In those patients, complete hematologic response and cytogenetic responses showed significant improvements in favor of IFN-alfa + Ara-C, with complete hematologic response relative risk (RR) of 1.15 (95% CI, 1.09-1.21), complete cytogenetic response RR of 1.87 (95% CI, 1.47-2.38), partial cytogenetic response RR of 1.48 (95% CI, 1.25-1.75), and major cytogenetic response RR of 1.61 (95% CI, 1.42-1.83), respectively. The overall 3-year survival rate in the IFN-alfa + Ara-C group was 86% compared with 79% in the IFN-alfa group (RR = 1.09; 95% CI, 1.03-1.14). In the other 2 studies, 5-year overall survival was 69% compared with 63%, respectively (RR = 1.08; 95% CI, 1.01-1.15). However, IFN-alfa and Ara-C involved higher risk of hematologic toxicity, gastrointestinal adverse events, and severe mucositis compared with IFN-alfa monotherapy (RR = 2.63 [95% CI, 1.94-3.56); RR = 3.38 [95% CI, 2.28-5.00], and RR = 8.84 [95% CI, 3.82-20.46], respectively). Weight loss and skin rash were also observed more frequently in the combination treatment group (RR = 2.00 [95% CI, 1.47-2.73) and RR = 3.75 [95% CI, 2.13-6.59], respectively). CONCLUSIONS: In patients with chronic myelogenous leukemia in the chronic phase, the combination of IFN-alfa + Ara-C demonstrated improved complete hematologic response, superior cytogenetic responses, and higher rates of 3- and 5-year survival than IFN-alfa alone. However, combination therapy is more likely to cause serious adverse effects. Well-designed studies will be required to determine the outcomes and adverse effects of the 2 drugs as treatment for patients with chronic myelogenous leukemia who cannot afford molecularly targeted drugs.
Authors: F Guilhot; C Chastang; M Michallet; A Guerci; J L Harousseau; F Maloisel; R Bouabdallah; D Guyotat; N Cheron; F Nicolini; J F Abgrall; J Tanzer Journal: N Engl J Med Date: 1997-07-24 Impact factor: 91.245
Authors: H M Kantarjian; S O'Brien; T L Smith; M B Rios; J Cortes; M Beran; C Koller; F J Giles; M Andreeff; S Kornblau; S Giralt; M J Keating; M Talpaz Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: Richard M Stone; Kathleen A Donohue; Wendy Stock; Vera Hars; Charles A Linker; Thomas Shea; Daniel J Deangelo; Guido Marcucci; Clara D Bloomfield; Richard A Larson Journal: Cancer Chemother Pharmacol Date: 2008-08-01 Impact factor: 3.333
Authors: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Jianqin Shan; Francis J Giles; Mary Beth Rios; Stefan H Faderl; William G Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Michael J Keating; Emil J Freireich; Moshe Talpaz Journal: Cancer Date: 2003-02-15 Impact factor: 6.860
Authors: A Ferrajoli; A M Liberati; P Caricchi; E Donti; E Morra; M Lazzarino; A R Betti; P Bernasconi; G Saglio Journal: Eur J Haematol Date: 1995-09 Impact factor: 2.997